RxDoctor Payments Data

Chad Alford, MD

Interventional Cardiology · Mobile, ALNPI 1114905429

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Abbott at 46.5% of the total. Reporting peaked in 2023 at $154 and has fallen 50.5% since, to $76 in 2025. That places this record below the midpoint for interventional cardiology clinicians in AL, where the typical reported total is $6,630.

$404in general payments, 2019–2025

Across 11 payments — averaging $36.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$187
  • Boehringer Ingelheim$59
  • Inari Medical, Inc.$59
  • Stryker$33
  • Hologic Sales And Service, LLC$25
  • Amgen$21
  • plus $18 from 1 others
$460,743in research payments, 2019–2025

Across 12 payments — averaging $38,395 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$448K
  • Merck$12K
  • Janssen Research & Development, LLC$15

What the payments were for

  • Food & beverage$404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$404 in reported general payments places this provider in the 0th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$174,242
Medicare patients
606
Services billed
1,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban457$441,646
XareltoRivaroxaban111$112,677
Repatha SureclickEvolocumab23$31,447
EntrestoSacubitril/Valsartan15$21,832
MultaqDronedarone Hcl21$15,527
Diltiazem 24hr Er (Cd)Diltiazem Hcl201$9,890
Metoprolol Succinate563$8,712
BrilintaTicagrelor12$7,593
Atorvastatin Calcium490$6,840
VascepaIcosapent Ethyl18$5,379
Potassium Chloride198$4,893
Amlodipine Besylate613$4,024
Rosuvastatin Calcium237$3,804
Ranolazine ErRanolazine45$3,749
Dabigatran EtexilateDabigatran Etexilate Mesylate12$3,684

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →